Bassil Dahiyat Sells 6,758 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 6,758 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total value of $80,420.20. Following the sale, the chief executive officer owned 567,792 shares of the company’s stock, valued at approximately $6,756,724.80. This represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Xencor Price Performance

Shares of NASDAQ:XNCR opened at $11.16 on Friday. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $818.47 million, a PE ratio of -9.00 and a beta of 0.95. The firm’s 50 day moving average price is $12.87 and its 200-day moving average price is $12.90. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $18.69.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same period in the prior year, the company earned ($0.62) earnings per share. The firm’s revenue was down 46.6% on a year-over-year basis. Equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Institutional Trading of Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Primecap Management Co. CA boosted its stake in Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after buying an additional 147,700 shares during the period. Vanguard Group Inc. boosted its position in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after buying an additional 61,692 shares during the period. BVF Inc. IL grew its stake in shares of Xencor by 160.3% during the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after buying an additional 4,393,579 shares during the last quarter. RTW Investments LP lifted its stake in shares of Xencor by 8.9% during the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after acquiring an additional 556,407 shares during the last quarter. Finally, State Street Corp grew its position in Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after acquiring an additional 833,423 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on XNCR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Cantor Fitzgerald increased their target price on Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. dropped their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Barclays raised their price objective on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Xencor currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Key Xencor News

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Xencor reported an EPS beat for the latest quarter and retains a strong liquidity position (high current/quick ratios), which cushions near?term financing risk and supports ongoing R&D programs. MarketBeat: Xencor company page
• Neutral Sentiment: CEO Bassil Dahiyat disclosed a sale of 6,758 shares at about $11.90 (roughly $80k). The sale reduced his stake by ~1.18% and may reflect routine diversification rather than a company-specific signal. SEC Form 4: CEO sale
• Negative Sentiment: Reported royalty rift: Alexion has cut off U.S. royalty payments to Xencor tied to Ultomiris, and Xencor said it is revising its Ultomiris royalty revenue forecast — a direct hit to near?term revenue and the main catalyst for the share decline. Benzinga: Royalty rift report Company announcement: royalty forecast change
• Negative Sentiment: Additional insider sales: SVP Celia Eckert and VP John Desjarlais sold shares the same day (small percent reductions of their holdings). The cluster of insider sales has heightened investor concern about insider timing and added to negative sentiment. InsiderTrades: insider sale report

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.